Neha Bhasin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Neha Bhasin has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
Li Zhang
3 shared publicationsElliott P. Vichinsky
Division of Hematology, Department of Pediatrics, University of California, San Francisco
2 shared publicationsRavi Sarode
Division of Transfusion Medicine and Hemostasis University of Texas Dallas Texas USA
2 shared publicationsAn Pham
Department of Pediatrics UT Southwestern University Dallas Texas USA
1 shared publicationAngela Rivers
Division of Hematology, Department of Pediatrics, University of California, San Francisco
1 shared publicationAyotola Ajayi
1 shared publication
Latest Publications
- Open Access
- 26 March 2026
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 10 (3)
Risk factors for venous thromboembolism in sickle cell disease
- 26 March 2026
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 10 (3)
Open AccessRisk factors for venous thromboembolism in sickle cell disease
- Open Access
- 1 December 2025
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 8 (12) , e2546345
Role of Menstrual Bleeding Assessments in Sickle Cell Clinics
Importance: The interplay between sickle cell disease (SCD) and reproductive health remains understudied. Menstruation is particularly complex in individuals with SCD, who may have delayed puberty, early menopause, abnormal uterine bleeding, and overlapping SCD-related and menstruation-related pain. Objective: To assess menstrual patterns in female patients with SCD, these patients’ access to and use of contraceptive therapy, and clinician practices associated with reproductive health. Design, Setting, and Participants: This cross-sectional survey study was conducted in 13 outpatient SCD centers across the US. Female patients with SCD who had reached menarche 12 or more months prior to enrollment between March 1, 2022, and May 31, 2024, and were not pregnant or post menopausal were included. Clinicians involved in the care of enrolled participants were also surveyed on a voluntary basis. Main Outcomes and Measures: Age-appropriate menstrual bleeding questionnaires were used to assess menstrual patterns, and global health was evaluated using the Patient-Reported Outcomes Measurement Information System mental and physical health scales. Newly designed patient-facing surveys were used to assessed SCD health and contraceptive use. Clinician-facing surveys assessed participants’ clinical history and care plans after reviewing the patient surveys. Results: A total of 211 participants (mean [SD] age 23.7 [10.1] years) were enrolled. All patient-facing surveys with a corresponding clinician survey were completed for 183 participants (86.7%). Abnormal uterine bleeding was noted in 52 participants (24.6%) and was associated with a higher rate of hospitalizations (59.1% hospitalized in this group vs 34.5% in the non–abnormal uterine bleeding group). Most participants (134 of 208 [64.4%]) endorsed sickle cell pain with menses. Among these participants, 42 (36.5%) had no emergency department (ED) visits, 51 (44.3%) had 1 to 3 ED visits, and 22 (19.1%) had 4 or more ED visits in the 6 months prior to enrollment compared with those who did not endorse sickle cell pain associated with menstruation (38 [58.5%], 24 [36.9%], and 3 [4.6%], respectively). In addition, among the participants who endorsed sickle cell pain, 57 (49.6%) had 0 hospitalizations, 48 (41.7%) had 1 to 3 hospitalizations, and 10 (8.7%) had 4 or more hospitalizations compared with those who did not endorse sickle cell pain associated with menstruation (50 [76.9%], 14 [21.5%], and 1 [1.5%], respectively). There was minimal use of hormonal contraception (40 of 208 participants [19.2%]), and 46 participants (22.1%) reported that they had never heard of these medications. After reviewing the patient survey, clinicians reported several intended steps to improve reproductive health for their patients, including reproductive health education (131 participants [72.4%]), referral to a reproductive health specialist (90 participants [49.7%]), or workup for iron deficiency (29 participants [16.0%]) or an underlying bleeding disorder (21 participants [11.6%]). Three participating sites established new multidisciplinary clinics for reproductive health and hematology during the enrollment period. Conclusions and Relevance: In this multicenter survey study of female individuals with SCD, sickle cell pain with menses was prevalent, and hormonal contraceptive use was low. The findings suggest that brief assessments may facilitate dialogue between female patients with SCD and their sickle cell clinicians and lay the groundwork for improved reproductive health and medical management.
- 1 December 2025
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 8 (12) , e2546345
Open AccessRole of Menstrual Bleeding Assessments in Sickle Cell Clinics
Importance: The interplay between sickle cell disease (SCD) and reproductive health remains understudied. Menstruation is particularly complex in individuals with SCD, who may have delayed puberty, early menopause, abnormal uterine bleeding, and overlapping SCD-related and menstruation-related pain. Objective: To assess menstrual patterns in female patients with SCD, these patients’ access to and use of contraceptive therapy, and clinician practices associated with reproductive health. Design, Setting, and Participants: This cross-sectional survey study was conducted in 13 outpatient SCD centers across the US. Female patients with SCD who had reached menarche 12 or more months prior to enrollment between March 1, 2022, and May 31, 2024, and were not pregnant or post menopausal were included. Clinicians involved in the care of enrolled participants were also surveyed on a voluntary basis. Main Outcomes and Measures: Age-appropriate menstrual bleeding questionnaires were used to assess menstrual patterns, and global health was evaluated using the Patient-Reported Outcomes Measurement Information System mental and physical health scales. Newly designed patient-facing surveys were used to assessed SCD health and contraceptive use. Clinician-facing surveys assessed participants’ clinical history and care plans after reviewing the patient surveys. Results: A total of 211 participants (mean [SD] age 23.7 [10.1] years) were enrolled. All patient-facing surveys with a corresponding clinician survey were completed for 183 participants (86.7%). Abnormal uterine bleeding was noted in 52 participants (24.6%) and was associated with a higher rate of hospitalizations (59.1% hospitalized in this group vs 34.5% in the non–abnormal uterine bleeding group). Most participants (134 of 208 [64.4%]) endorsed sickle cell pain with menses. Among these participants, 42 (36.5%) had no emergency department (ED) visits, 51 (44.3%) had 1 to 3 ED visits, and 22 (19.1%) had 4 or more ED visits in the 6 months prior to enrollment compared with those who did not endorse sickle cell pain associated with menstruation (38 [58.5%], 24 [36.9%], and 3 [4.6%], respectively). In addition, among the participants who endorsed sickle cell pain, 57 (49.6%) had 0 hospitalizations, 48 (41.7%) had 1 to 3 hospitalizations, and 10 (8.7%) had 4 or more hospitalizations compared with those who did not endorse sickle cell pain associated with menstruation (50 [76.9%], 14 [21.5%], and 1 [1.5%], respectively). There was minimal use of hormonal contraception (40 of 208 participants [19.2%]), and 46 participants (22.1%) reported that they had never heard of these medications. After reviewing the patient survey, clinicians reported several intended steps to improve reproductive health for their patients, including reproductive health education (131 participants [72.4%]), referral to a reproductive health specialist (90 participants [49.7%]), or workup for iron deficiency (29 participants [16.0%]) or an underlying bleeding disorder (21 participants [11.6%]). Three participating sites established new multidisciplinary clinics for reproductive health and hematology during the enrollment period. Conclusions and Relevance: In this multicenter survey study of female individuals with SCD, sickle cell pain with menses was prevalent, and hormonal contraceptive use was low. The findings suggest that brief assessments may facilitate dialogue between female patients with SCD and their sickle cell clinicians and lay the groundwork for improved reproductive health and medical management.
- Open Access
- 7 October 2024
- Published by Wiley in Transfusion
- Vol. 64 (11) , 2095-2103
Physician perspectives about the diagnosis and management of acute chest syndrome
Background: Acute chest syndrome (ACS) is the leading cause of mortality, accounting for 25% of all deaths among individuals with sickle cell disease (SCD). There is a lack of evidence‐based laboratory and clinical risk stratification guidelines for the diagnosis and management of ACS.Study Design and Methods: To better understand physician practices for the management of ACS in the United States, we created an ACS Working Group including hematology and transfusion medicine physicians from four different SCD treatment centers in the United States. The working group created a physician survey that included physician demographics and ACS diagnostic criteria that they had to rate. The survey also included three case scenarios to assess physician attitudes about the management of ACS. Management options included supportive and preventive strategies in addition to transfusion therapy options.Results: Out of 455 physicians who received the survey, 195 responded (response rate = 43%). The respondents were primarily hematology/oncology physicians. The responses showed wide variability among physicians in how diagnostic criteria for ACS are used and how physicians risk‐stratify ACS patients in their practice. The responses also reflected variability in the use of transfusions for ACS.Discussion: Based on our results, we conclude that ACS is diagnosed and managed inconsistently among expert physicians, especially in their transfusion practices due to a lack of consensus on risk stratification criteria. Our data suggest an urgent need for well‐designed prospective studies to provide evidence‐based guidelines and minimize management variability among physicians who care for individuals with SCD and ACS.
- 7 October 2024
- Published by Wiley in Transfusion
- Vol. 64 (11) , 2095-2103
Open AccessPhysician perspectives about the diagnosis and management of acute chest syndrome
Background: Acute chest syndrome (ACS) is the leading cause of mortality, accounting for 25% of all deaths among individuals with sickle cell disease (SCD). There is a lack of evidence‐based laboratory and clinical risk stratification guidelines for the diagnosis and management of ACS.Study Design and Methods: To better understand physician practices for the management of ACS in the United States, we created an ACS Working Group including hematology and transfusion medicine physicians from four different SCD treatment centers in the United States. The working group created a physician survey that included physician demographics and ACS diagnostic criteria that they had to rate. The survey also included three case scenarios to assess physician attitudes about the management of ACS. Management options included supportive and preventive strategies in addition to transfusion therapy options.Results: Out of 455 physicians who received the survey, 195 responded (response rate = 43%). The respondents were primarily hematology/oncology physicians. The responses showed wide variability among physicians in how diagnostic criteria for ACS are used and how physicians risk‐stratify ACS patients in their practice. The responses also reflected variability in the use of transfusions for ACS.Discussion: Based on our results, we conclude that ACS is diagnosed and managed inconsistently among expert physicians, especially in their transfusion practices due to a lack of consensus on risk stratification criteria. Our data suggest an urgent need for well‐designed prospective studies to provide evidence‐based guidelines and minimize management variability among physicians who care for individuals with SCD and ACS.
- Open Access
- 3 September 2023
- Published by Elsevier in Transfusion Medicine Reviews
- Vol. 37 (3) , 150755
Acute Chest Syndrome in Sickle Cell Disease
- 3 September 2023
- Published by Elsevier in Transfusion Medicine Reviews
- Vol. 37 (3) , 150755
Open AccessAcute Chest Syndrome in Sickle Cell Disease
- Open Access
- 10 August 2022
- Published by Elsevier in Thrombosis Research
- Vol. 218, 48-51
Association of low serum albumin with venous thrombosis in pediatric patients
- 10 August 2022
- Published by Elsevier in Thrombosis Research
- Vol. 218, 48-51
Open AccessAssociation of low serum albumin with venous thrombosis in pediatric patients
- 11 May 2021
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 44 (2) , e428-e430
Multifocal Osteonecrosis in a 3-Year-old Child With Sickle Beta Plus Thalassemia
Sickle beta+thalassemia is considered to be a mild form of sickle cell disease. However, some patients with mild disease can present with osteonecrosis. Here, we present a rare 3-year-old male who presented with acute pain, a baseline hemoglobin of 13 g/dL, who acutely developed multifocal osteonecrosis, and improved with partial exchange transfusion and hydroxyurea therapy.
- 11 May 2021
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 44 (2) , e428-e430
Multifocal Osteonecrosis in a 3-Year-old Child With Sickle Beta Plus Thalassemia
Sickle beta+thalassemia is considered to be a mild form of sickle cell disease. However, some patients with mild disease can present with osteonecrosis. Here, we present a rare 3-year-old male who presented with acute pain, a baseline hemoglobin of 13 g/dL, who acutely developed multifocal osteonecrosis, and improved with partial exchange transfusion and hydroxyurea therapy.